Randomized double-blind placebo-controlled trial of Jianpijieyu Prescription in the treatment of mild to moderate depressio
- Conditions
- depression
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- Not specified
1) Meet the diagnostic criteria for DSM-V depression;
2) According to the TCM syndrome differentiation, it is the syndrome of deficiency of heart and spleen or stagnation of liver qi;
3) Men and women aged 18-65;
4) 17 items of Hamilton Depression Scale (HAMD) score =18 and =24, and one item of depression in HAMD score =2;
5) The subject agrees and signs the informed consent form.
1) Suicidal, HAMD suicide =2 points;
2) Hamilton Anxiety Scale (HAMA) score =29 for patients with severe anxiety symptoms;
3) Patients with serious or unstable heart, liver, kidney, endocrine, blood and other internal diseases;
4) Depressive episodes secondary to physical diseases;
5) Organic mental disorders, schizophrenia, bipolar disorder;
6) Depressive disorders caused by psychoactive substances (e.g., alcohol, tobacco, opioids, etc.) and non-addictive substances;
7) Have taken sedative, hypnotic, anti-depressant and other psychiatric drugs (such as risperidone and olanzapine) within one month;
8) Diabetic patients;
9) Allergic to the drug in this study;
10) Pregnant or lactating women;
11) Those who have received other clinical trials for depression in the past 3 months;
12) Those who are receiving targeted drug therapy.
Study & Design
- Study Type
- Interventional study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method HAMD-17;
- Secondary Outcome Measures
Name Time Method HAMA;TCM syndrome integration;SDS;